Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Liabilities: 2023-2024

Historic Total Liabilities for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $25.4 million.

  • BioLineRx's Total Liabilities fell 54.17% to $23.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $140.7 million, marking a year-over-year decrease of 15.63%. This contributed to the annual value of $25.4 million for FY2024, which is 49.81% down from last year.
  • BioLineRx's Total Liabilities amounted to $25.4 million in FY2024, which was down 49.81% from $50.7 million recorded in FY2023.
  • Over the past 5 years, BioLineRx's Total Liabilities peaked at $50.7 million during FY2023, and registered a low of $25.4 million during FY2024.
  • Moreover, its 2-year median value for Total Liabilities was $38.1 million (2023), whereas its average is $38.1 million.
  • Data for BioLineRx's Total Liabilities shows a maximum YoY plummeted of 49.81% (in 2024) over the last 5 years.
  • Over the past 2 years, BioLineRx's Total Liabilities (Yearly) stood at $50.7 million in 2023, then crashed by 49.81% to $25.4 million in 2024.